Maintenance chemotherapy in rhabdomyosarcoma: the new standard of care
Mené dans 14 pays européens sur 371 patients atteints d'un rhabdomyosarcome à haut risque de récidive (âge : 6 mois-21 ans), cet essai de phase III évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité d'une chimiothérapie d'entretien à base de vinorelbine et de faibles doses de cyclophosphamide (durée médiane de suivi : 60,3 mois)
In The Lancet Oncology, Gianni Bisogno and colleagues present the results of an important frontline, phase 3 randomised study in children and adolescents with rhabdomyosarcoma. This trial was done by the European paediatric Soft tissue sarcoma Study Group (EpSSG) cooperative group, in children and adolescents with previously untreated high-risk non-metastatic rhabdomyosarcoma, and shows the benefit of six cycles of vinorelbine and oral cyclophosphamide maintenance chemotherapy in this subgroup of patients.
The Lancet Oncology , commentaire, 2018